← Back to Clinical Trials
Recruiting NCT07111364

NCT07111364 Construction of a Deep Learning-Based Precise Diagnostic Framework for Bladder Tumors Using Ultrasound: A Multicenter, Ambispective Cohort Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07111364
Status Recruiting
Phase
Sponsor Peking University First Hospital
Condition Deep Learning
Study Type OBSERVATIONAL
Enrollment 400 participants
Start Date 2025-05-27
Primary Completion 2026-05-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 85 Years
Study Type OBSERVATIONAL
Interventions
observational diagnostic model development

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 400 participants in total. It began in 2025-05-27 with a primary completion date of 2026-05-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to develop an ultrasound image-based deep learning system to enable automatic segmentation, T-staging, and pathological grading prediction of bladder tumors. It seeks to enhance the objectivity, accuracy, and efficiency of bladder cancer diagnosis, reduce reliance on physician experience, and provide support for precision medicine and resource optimization.

Eligibility Criteria

Inclusion Criteria:① Suspected bladder mass detected by abdominal ultrasound (age ≥18 years);② Patients scheduled for surgical treatment of bladder tumors. Exclusion Criteria: * Age \>85 years; * Patients unable to undergo abdominal/transrectal ultrasound (e.g., uncooperative individuals, technically inadequate images); * History of bladder tumor surgery, radiotherapy, chemotherapy, or systemic therapy within 3 months; ④ Patients with indwelling medical devices (e.g., double-J ureteral stents, urinary catheters); * Failure to undergo bladder tumor surgery within 2 weeks post-ultrasound; ⑥ Non-urothelial carcinoma or pathologically unconfirmed diagnoses.

Contact & Investigator

Central Contact

Zheng Zhang

✉ doczhz@aliyun.com

📞 +86 139 0137 1490

Frequently Asked Questions

Who can join the NCT07111364 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Deep Learning. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07111364 currently recruiting?

Yes, NCT07111364 is actively recruiting participants. Contact the research team at doczhz@aliyun.com for enrollment information.

Where is the NCT07111364 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT07111364 clinical trial?

NCT07111364 is sponsored by Peking University First Hospital. The trial plans to enroll 400 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology